WO1996022080A1 - Pharmaceutical excipient having improved compressibility - Google Patents
Pharmaceutical excipient having improved compressibility Download PDFInfo
- Publication number
- WO1996022080A1 WO1996022080A1 PCT/US1996/000539 US9600539W WO9622080A1 WO 1996022080 A1 WO1996022080 A1 WO 1996022080A1 US 9600539 W US9600539 W US 9600539W WO 9622080 A1 WO9622080 A1 WO 9622080A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microcrystalline cellulose
- surfactant
- composition
- weight
- excipient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/2036—Silicones; Polysiloxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Definitions
- the present invention relates to a novel excipient for use in the manufacture of pharmaceuticals, and in particular, solid dosage forms such as tablets which include one or more active ingredients.
- the material to be compressed into the dosage form possess certain physical characteristics which lend themselves to processing in such a manner.
- the material to be compressed must be free-flowing, must be lubricated, and, importantly, must possess sufficient cohesiveness to insure that the solid dosage form remains intact after compression.
- the tablet is formed by pressure being applied to the material to be tabletted on a tablet press.
- a tablet press includes a lower punch which fits into a die from the bottom and a upper punch having a corresponding shape and dimension which enters the die cavity from the top after the tabletting material fills the die cavity The tablet is formed by pressure applied on the lower and upper punches.
- the ability of the material to flow freely into the die is important in order to insure that there is a uniform filling of the die and a continuous movement of the material from the source of the material, e.g. a feeder hopper.
- the lubricity of the material is crucial in the preparation of the solid dosage forms since the compressed material must be readily ejected from the punch faces Since most drugs have none or only some of these properties, methods of tablet formulation have been developed in order to impart these desirable character ⁇ istics to the material(s) which is to be compressed into a solid dosage form.
- the material to be compressed into a solid dosage form includes one or more excipients which impart the free-flowing, lubrication, and cohesive properties to the drug(s) which is being formulated into a dosage form.
- Lubricants are typically added to avoid the material(s) being tabletted from sticking to the punches
- Commonly used lubricants include magnesium stearate and calcium stearate. Such lubricants are commonly included in the final tabletted product in amounts of less than 1% by weight.
- solid dosage forms In addition to lubricants, solid dosage forms often con'ain diluents. Diluents are frequently added in order to increase the bulk weight of the material to be tabletted in order to make the tablet a practical size for compression. This is often necessary where the dose of the drug is relatively small.
- Binders are agents which impart cohesive qualities to the powdered material(s) Commonly used binders include starch, and sugars such as sucrose, glucose, dextrose, and lactose.
- Disintegrants are often included in order to ensure that the ultimately prepared compressed solid dosage form has an acceptable disintegration rate in an environment of use (such as the gastrointestinal tract).
- Typical disintegrants include starch derivatives and salts of carboxymethylcellulose.
- Dry granulation procedures may be utilized where one of the constituents, either the drug or the diluent, has sufficient cohesive properties to be tabletted
- the method includes mixing the ingredients, slugging the ingredients, dry screening, lubricating and finally compressing the ingredients.
- the powdered material(s) to be included in the solid dosage form is compressed directly without modifying the physical nature of the material itself
- the wet granulation procedure includes mixing the powders to be incorporated into the dosage form in, e.g., a twin shell blender or double-cone blender and thereafter adding solutions of a binding agent to the mixed powders to obtain a granulation. Thereafter, the damp mass is screened, e.g., in a 6- or 8-mesh screen and then dried, e.g., via tray drying, the use of a fluid-bed dryer, spray-dryer, radio-frequency dryer, microwave, vacuum, or infra-red dryer.
- direct compression is limited to those situations where the drug or active ingredient has a requisite crystalline structure and physical characteristics required for formation of a pharmaceutically acceptable tablet.
- the drug itself is to be administered in a relatively high dose (e.g., the drug itself comprises a substantial portion of the total tablet weight)
- excipients are added to the formulation which impart good flow and compression characteristics to the material as a whole which is to be compressed. Such properties are typically imparted to these excipients via a pre- processing step such as wet granulation, slugging, spray drying, spheronization, or crystallization.
- Use I direct compression excipients include processed forms of cellulose, sugars, and dicalcium phosphate dihydrate, among others.
- microcrystalline cellulose has been utilized extensively in the pharmaceutical industry as a direct compression vehicle for solid dosage forms.
- Microcrystalline cellulose is commercially available under the tradename EMCOCEL® from Edward Mendell Co., Inc. and as Avicel® from FMC Corp.
- EMCOCEL® from Edward Mendell Co., Inc.
- Avicel® from FMC Corp.
- microcrystalline cellulose is generally considered to exhi' '! superior compressibility and disin ⁇ tegration properties
- Another limitation of direct compression as a method of tablet manufacture is the size of the tablet.
- a pharmaceutical formulator may choose to wet granulate the active with other excipients to attain an acceptably sized tablet with the desired compact strength
- the amount of filler/binder or excipients needed in wet granulation is less than that required for direct compression since the process of wet granulation contributes to some extent toward the desired physical properties of a tablet.
- wet granulation is widely used in the industry in the preparation of solid dosage forms.
- wet granulation as compared to direct compression because this method has a greater probability of overcoming any problems associated with the physical characteristics of the various ingredients in the formulation, thereby providing a material which has the requisite flow and cohesive characteristics necessary to obtain an acceptable solid dosage form.
- the popularity of the wet granulation process as compared to the direct compression process is based on at least three advantages.
- wet granulation provides the material to be compressed with better wetting properties, particularly in the case of hydrophobic drug substances.
- the addition of a hydrophilic excipient makes the surface of a hydrophobic drug more hydrophilic, easing disintegration and dissolution.
- the content uniformity of the solid dosage forms is generally improved.
- the granules thereby obtained should contain approximately the same amount of drug.
- segregation of the different ingredients of the material to be compressed is avoided. Segregation is a potential problem with the direct compression method.
- the particle size and shape of the particles comprising the granulate to be compressed are optimized via the wet granulation process. This is due to the fact that when a dry solid is wet granulated, the binder "glues" particles together, so that they agglomerate in the granules which are more or less spherical.
- microcrystalline cellulose Due to the popularity of microcrystalline cellulose, pharmaceutical formulators have deemed it desirable to include this excipient in a formulation which is wet granulated prior to tabletting. Unfortunately, currently-available microcrystalline cellulose does not hold to the typical principle that the amount of filler/binder needed in wet granulation is less than that in direct compression. It is known that the exposure of the microcrystalline cellulose to moisture in the wet granulation process severely reduces the compressibility of this excipient. The loss of compressibility of microcrystalline cellulose is particularly problematic where the formulation dictates that the final product will be relatively large in the environment of use.
- the loss of compressibility of the microcrystalline cellulose dictates that a larger amount of this material may be needed to obtain an acceptably compressed final product.
- the additional amount of microcrystalline cellulose needed adds cost to the preparation, but more importantly adds bulk, making the product more difficult to swallow.
- 4,159,345 (Takeo, et al.) describes an excipient which consists essentially of a microcrystalline cellulose having an average degree of polymerization of 60 to 375 and obtained through acid hydrolysis or alkaline oxidative degradation of a cellulosic substance selected from linters, pulps and regenerated fibers.
- the microcrystalline cellulose is said to be a white cellulosic powder having an apparent specific volume of 1.6-3.1 cc/g, a repose angle of 35 ° to 42°, a 200-mesh sieve residue of 2 to 80% by weight and a tapping apparent specific volume of at least 1 .4 cc/g.
- a paniculate co-processed microcrystalline cellulose and calcium carbonate composition wherein the respective components are present in a weight ratio of 75:25 to 35:65.
- the co- processed composition is said to be prepared by forming a well-dispersed aqueous slurry of microcrystalline cellulose and calcium carbonate and then drying the slurry to yield a paniculate product.
- the combination of these two ingredients is said to provide a lower cost excipient which has tabletting characteristics similar to those of microcrystalline cellulose and which would satisfy a need for an economical excipient with good performance that is desired by the vitamin market.
- European Patent Application EP 0609976A1 (assigned to Asahi Kasei Kabushiki Kaisha) describes an excipient comprising white powdery microcrystalline cellulose having an average degree of polymerization of from 100 to 375, preferably from 190 to 210, and an acetic acid holding capacity of 280% or more, preferably from 290 to 370%.
- the excipient is said to exhibit high compactability and a high rate of disintegration and is said to be obtained by heat- treating an aqueous dispersion of purified cellulose particles, which has a solids content of 40% or less by weight, at 100°C or more, followed by drying, or by sub ⁇ jecting an aqueous dispersion of purified cellulose particles having a solids content of 23% or less by weight to thin film-forming treatment and drying the resultant thin film.
- the excipient is said to possess a high compressibility, and a good balance of compactability and rate of disintegration There still remains a need in the industry for a pharmaceutical excipient which possesses excellent compressibility whether utilized in a direct compression or wet granulation procedure.
- the present invention is directed to an excipient comprising a paniculate agglomerate of coprocessed microcrystalline cellulose and a surfactant.
- the surfactant is an ionic surfactant and most preferably, the surfactant is an anionic surfactant.
- the amount of surfactant coprocessed with the microcrystalline cellulose is dependent, in part, upon the type of surfactant selected.
- the amount is generally described as an effective amount, i.e. an amount which enhances or augments the compressibility of the microcrystalline cellulose.
- One particularly preferred surfactant is the anionic surfactant sodium lauryl sulfate (SLS). This surfactant is present in an amount of from about 0.1% to about 0.5% by weight of the microcrystalline cellulose. Preferably, however, the surfactant is present in amounts of from about 0.15 to about 0.4% and most preferably, in amounts ranging from about 0.2 to about 0.3% by weight.
- SLS sodium lauryl sulfate
- the microcrystalline cellulose and surfactant are in intimate association with each other, and the surfactant portion of the agglomerate is in the form of an aqueous solution prior to being coprocessed with microcrystalline cellulose.
- the present invention is further directed to an aqueous slurry useful in the preparation of a compressible excipient useful in dry and wet granulation formulation methods, comprising a mixture of microcrystalline cellulose and from about 0.1% to about 0.5% of a surfactant such as sodium lauryl sulfate, by weight relative to the microcrystalline cellulose.
- the solids content of the aqueous slurry is from about 0.5% to about 25%, by weight, preferably from about 15% to about 20%) by weight, and most preferably from about 17% to about 1 % by weight.
- the present invention is further directed to a mixture of an active ingredient(s) and an excipient comprising a particulate agglomerate of coprocessed microcrystalline cellulose and a surfactant, the surfactant being present in an amount of from about 0.1% to about 0.5% by weight based on the weight of the microcrystalline cellulose.
- the microcrystalline cellulose and surfactant are in intimate association with each other and the ratio of active ingredient to excipient is from about 1 :99 to about 99: 1 , by weight.
- the present invention is further directed to a granulate of an active ingredient(s) and the novel excipient described herein, wherein the active ingredient(s) and excipient have been subjected to a wet granulation procedure.
- the present invention is also directed to a compressed solid dosage form comprising an active ingredient(s) and the novel excipient described herein, wherein the active ingredient(s) and excipient have been directly compressed into the solid dosage form or have been subjected to a wet granulation procedure and thereafter compressed into the solid dosage form.
- the compressed solid dosage form provides a suitable immediate release dissolution profile of the active ingredient(s) when exposed to aqueous solutions during in-vitro dissolution testing, and provides a release of dnig in an environment of use which is considered bioavailable.
- the dissolution profile of the solid dosage form is modified to provide a controlled or sustained release dissolution profile.
- the present invention is further directed to a method of maintaining and/or enhancing the compressibility of microcrystalline cellulose.
- the method includes forming an aqueous slurry containing a mixture of microcrystalline cellulose and a surfactant, and drying the slurry to obtain microcrystalline cellulose-based excipient particles in which the surfactant has been integrated with the microcrystalline cellulose particles.
- the slurry contains from about 0.5% to about 25% by weight microcrystalline cellulose, with amounts of from about 15% to about 20% being preferred.
- the surfactant included in the slurry is preferably an anionic surfactant such as SLS and is present in amounts ranging from about 0.1% to about 0.5% by weight of the MCC.
- novel excipient described herein is free-flowing, possesses excellent disintegration properties, and importantly, in certain embodiments possesses improved compressibility relative to normal "off-the-shelf commercially available microcrystalline cellulose when directly compressed.
- the advantages of the novel excipient described herein are especially realized in pharmaceutical formulations prepared using wet granulation techniques.
- the novel excipient When utilized in wet granulation techniques, the novel excipient surprisingly provides a compressibility which is substantially improved in preferred embodiments in comparison to the compress ⁇ ibility of normal "off-the-shelf commercially available microcrystalline cellulose used in wet granulation and is even comparable to "off-the-shelf microcrystalline cellulose used in direct compression techniques In other embodiments, the novel excipient surprisingly provides a compressibility which is substantially superior to the compressibility of normal "off-the-shelf commercially available microcrystalline cellulose used in direct compression techniques.
- the term "environn, ntal fluid" is meant for purposes of the invention to encompass, e.g., an aqueous solution, or gastrointestinal fluid.
- sustained release it is meant for purposes of the invention that the therapeutically active medicament is released from the formulation at a controlled rate such that therapeutically beneficial blood levels (but below toxic levels) of the medicament are maintained over an extended period of time, e.g., providing a 12 hour or a 24 hour dosage form.
- bioavailable it is meant for purposes of the invention that the therapeutically active medicament is absorbed from the sustained release formulation and becomes available in the body at the intended site of drug action.
- surfactant it is meant for purposes of the present invention that the material is a surface active agent which displays wetting, detergent or soap-like qualities as those agents are understood by those of ordinary skill in the art.
- Figure 1 graphically shows a comparison of the tensile strength of tablets prepared in accordance with the invention and prior art tablets.
- Figure 2 graphically shows a comparison of the tensile strength of tablets prepared in accordance with the invention to contain MCC coprocessed with SLS, tablets containing MCC coprocessed with docusate sodium and prior art tablets prepared to contain only unmodified MCC.
- Figure 3 graphically illustrates a comparison of the tensile strength of tablets prepared using MCC coprocessed with polysorbate 40, tablets prepared with the novel SLS coprocessed MCC and tablets prepared with MCC alone
- Figure 4 graphically illustrates a comparison of the tensile strength of tablets prepared using MCC coprocessed with polydimethyl siloxane (simethicone) , tablets prepared using coprocessed MCC-SLS and prior art tablets prepared to contain only unmodified MCC.
- Microcrystalline cellulose is a well-known tablet diluent, binder and disintegrant. Its chief advantage over other excipients is that it can be directly compressed into self-binding tablets which disintegrate rapidly when placed into water.
- This widely-used ingredient is prepared by partially depolymerizing cellulose obtained as a pulp from fibrous plant material with dilute mineral acid solutions. Following hydrolysis, the hydrocellulose thereby obtained is purified via filtration and an aqueous slurry is spray dried to form dry, white odorless, tasteless crystalline powder of porous particles of varicas sizes. Another method of preparing microcrystalline cellulose is disclosed in U.S. Patent No. 3, 141,875.
- This reference discloses subjecting cellulose to the hydrolytic action of hydrochloric acid at boiling temperatures so that amorphous cellulosic material can be removed and aggregates of crystalline cellulose are formed.
- the aggregates are collected by filtration, washed with water and aqueous ammonia and disintegrated into small fragments, often called cellulose crystallites by vigorous mechanical means such as a blender.
- Microcrystalline cellulose is commercially available in several grades which range in average particle size from 20 to 200 microns. Microcrystalline cellulose is water-insoluble, but the material has the ability to draw fluid into a tablet by capillary action. The tablets then swell on contact and the microcrystalline cellulose thus acts as a disintegrating agent.
- microcrystalline cellulose has an apparent density of about 0.28 g/cm' and a tap density of about 0.43 g/cm 3 . Handbook of Pharmaceutical Excipients, pages 53-55.
- microcrystalline cellulose When utilized in pharmaceutical applications, microcrystalline cellulose is typically used as a tablet binder/diluent in wet granulation and direct compression formulations in amounts of 3-30% of the formulation, or more. However, it is known to use more or less microcrystalline cellulose in pharmaceutical products, depending upon the requirements of the formulation.
- the surfactants which may be used in the present invention generally include all pharmaceutically-acceptable surfactants.
- the surfactant is an ionic surfactant and most preferably, the surfactant is an anionic surfactant.
- Suitable pharmaceutically-acceptable anionic surfactants include, for example, those containing carboxylate, sulfonate, and sulfate ions. Those containing carboxylate ions are sometimes referred to as soaps and are generally prepared by saponification of natural fatty acid glycerides in alkaline solutions. The most common cations associated with these surfactants are sodium, potassium, ammonium and triethanolamine. The chain length of the fatty acids range from 12 to 18.
- alkyl sulfates are available as surfactants
- one particularly preferred surfactant is sodium lauryl sulfate.
- sodium lauryl sulfate has been used as an emulsifying agent in amounts of up to about 0.1% by weight of the formulation. It is not believed that surfactants such as SLS have been included in coprocessed MCC compositions. Moreover, it is not believed that surfactants have been used in the amounts described herein to improve the compressibility of MCC especially in wet granulations.
- Sodium lauryl sulfate is a water-soluble salt, produced as a white or cream powder, crystals, or flakes and is used as a wetting agent and detergent. Also known as dodecyl sodium sulfate, SLS is actually a mixture of sodium alkyl sulfates consisting chiefly of sodium lauryl sulfate. Sodium lauryl sulfate is also known as sulfuric acid monododecyl ester sodium salt. Furthermore, sodium lauryl sulfate is readily available from commercial sources such as Sigma or Aldrich in both solid form and as a solution The solubility of SLS is about 1 gm per 10 ml/water.
- the fatty acids of coconut oil consisting chiefly of lauric acid, are catalytically hydrogenated to form the corresponding alcohols.
- the alcohols are then esterified with sulfuric acid (sulfated) and the resulting mixture of alkyl bisulfates (alkyl sulfuric acids) is converted into sodium salts by reacting with alkali under controlled conditions of pH.
- anionic surfactants include docusate salts such as the sodium salt thereof.
- suitable anionic surfactants include, without limitation, alkyl carboxylates, acyl lactylates, alkyl ether carboxylates, N-acyl sarcosinates, polyvalent alkyl carbonates, N-acyl glutamates, fatty acid, polypeptide condensates and sulfuric acid esters
- amphoteric amphipathic/amphiphilic surfactants
- non-ionic surfactants non-ionic surfactants
- cationic surfactants are included in the coprocessed compositions of the invention.
- surfactants can be included to replace some or even all of the preferred anionic surfactant. It is preferred, however, that the surfactant comprise an anionic surfactant.
- Suitable pharmaceutically-acceptable non-ionic surfactants such as, for example, polyoxyethylene compounds, lecithin, ethoxylated alcohols, ethoxylated esters, ethoxylated amides, polyoxypropylene compounds, propoxylated alcohols, ethoxylated/propoxylated block polymers, propoxylated esters, alkanolamides, amine oxides, fatty acid esters of polyhydric alcohols, ethylene glycol esters, diethylene glycol esters, propylene glycol esters, glycerol esters, polyglycerol fatty acid esters, SP ⁇ N's (e.g., sorbitan esters), TWEEN's (i.e., sucrose esters), glucose
- Suitable pharmaceutically-acceptable surfactants include acacia, benzalkonium chloride, cholesterol, emulsifying wax, glycerol monostearate, lanolin alcohols, lecithin, poloxamer, polyoxyethylene, and castor oil derivatives.
- Those skilled in the art will further appreciate that the name and/or method of preparation of the surfactant utilized in the present invention is not determinative of the usefulness of the product. Rather, as previously mentioned, it has been surprisingly discovered that it is the physical characteristics of surfactants, especially those of the anionic class such as sodium lauryl sulfate, which are critical. In particular, it has been discovered that when an anionic surfactant such as SLS is coprocessed with microcrystalline cellulose in the amounts described herein, improved microcrystalline cellulose products of the invention result.
- the novel excipient of the invention utilizes an anionic surfactant, it has been found that the resultant excipient product surprisingly provides a com ⁇ pressibility which is substantially improved in preferred embodiments even in comparison to the compressibility of normal "off-the-shelf commercially available microcrystalline cellulose used in direct compression techniques.
- microcrystalline cellulose is substantially water insoluble
- the particle size of this ingredient in the well-dispersed aqueous slurry is directly related to its particle size as it was introduced into the aqueous solution.
- Most surfactants tend to be water soluble.
- Sodium lauryl sulfate for example, is relatively soluble in water (1 g/l Oml) and, therefore, dissolves in the aqueous slurry.
- the coprocessed products of the present invention are not solely limited to those which contain a dissolved surfactant.
- the contemplated compositions can also be prepared from slurries which contain a dispersion of the surfactant as well as the MCC.
- the suspension is dried to provide a plurality of microcrystalline cellulose-based excipient particles having enhanced compressibility.
- the aqueous dispersion of microcrystalline cellulose and surfactant is brought together with a sufficient volume of hot air to produce evaporation and drying of the liquid droplets.
- the highly dispersed slurry of microcrystalline cellulose and surfactant is pumpable and capable of being atomized. It is sprayed into a current of warm filtered air, which supplies the heat for evaporation and conveys a dried product to a collecting device. The air is then exhausted with the removed moisture.
- the resultant spray-dried powder particles are approximately spherical in shape and are relatively uniform in size, thereby possessing excellent flowability.
- the coprocessed product consists of microcrystalline cellulose and surfactant in intimate association with each other.
- the coprocessed particles are described herein as including an agglomerate of microcrystalline cellulose and surfactant in intimate association with each other.
- intimate association it is meant that the surfactant has in some manner been integrated with the microcrystalline cellulose particles, e.g., via a partial coating of the microcrystalline particles, as opposed to a chemical interaction of the two ingredients.
- intimate association is therefore deemed for purposes of the present description as being synonymous with "integrated” or "united”.
- the coprocessed particles are not necessarily uniform or homogeneous.
- the microcrystalline cellulose and SLS are coprocessed, resulting in an intimate association of these in ⁇ gredients, rather than being combined, e.g., as a dry mixture.
- the aqueous slurry of the microcrystalline cellulose and surfactant are introduced into the spray dryer as a single aqueous medium.
- it is possible to separately introduce each ingredient into separate aqueous media which are then combined Other procedures for combining the microcrystalline cellulose and surfactant known to those skilled in the art are deemed to be equivalent to the spray-drying technique described above, and are further deemed to be encompasses by the appended claims.
- the coprocessing of the microcrystalline cellulose and SLS is accomplished by forming a well- dispersed aqueous slurry of microcrystalline cellulose in which the SLS has been dissolved, and thereafter drying the slurry and forming a plurality of microcrystalline cellulose-based excipient particles.
- microcrystalline cellulose is first added to an aqueous solution so that a slurry or suspension containing from about 0.5% to about 25% microcrystalline cellulose in the form of solids is obtained.
- the slurry or suspension contains from about 15% to 20% microcrys- talline cellulose and most preferably from about 17% to about 19% microcrystalline cellulose.
- the pH of the slurry is adjusted to about neutral with ammonium hydroxide, sodium hydroxide, and mixtures thereof or the like.
- the suspension is kept under constant agitation for a sufficient time to assure a uniform distribution of the solids prior to being combined with the SLS.
- the SLS is added to the suspension or slurry in amounts ranging from 0 1% to about 0.5% by weight, based on the amount of microcrystalline cellulose, amounts from about 0.15% to about 0.4% are preferred while amounts of from about 0.2% to about 0.3% by weight are especially preferred.
- the SLS can be added to the suspension as either a solid or in solution form
- the microcrystalline cellulose is thus well-dispersed in the slurry or suspension and the surfactant is dissolved therein prior drying and forming the novel particles.
- other useful surfactants can be used in like amounts or even greater amounts, i.e. up to 5% by weight or even more.
- the usable concentration range for the selected surfactant depends in part upon not only its molecular weight but also its degree of foaming, particularly when present in agitated slurries which will be spray dried to form the desired paniculate.
- surfactants other than SLS are coprocessed with the microcrystalline cellulose
- the surfactant will be present in an amount which enhances the compressibility of the MCC and yet does not have a degree of foaming which would substantially inhibit spray drying.
- ihe suspension be dried using spray-drying techniques, as they are known in the art Other drying techniques, however, such as flash drying, ring drying, micron drying, tray drying, vacuum drying, radio-frequency drying, and possibly microwave drying, can also be used.
- spray-drying techniques such as flash drying, ring drying, micron drying, tray drying, vacuum drying, radio-frequency drying, and possibly microwave drying.
- the novel compressible particles will have different particle sizes, densities, pH, moisture content, etc.
- the paniculate coprocessed product of the present invention possesses desirable performance attributes that are not present when the combination of microcrystalline cellulose and SLS and optionally present other surfactants are combined as a dry mixture. It is believed that the beneficial result obtained by the combination of these two materials is due to the fact that the two materials are intimately associated with each other. It has also been found that intimate association of MCC and other detergent-like materials such as simethicone, even when they are dissolved/dispersed in the aqueous solutions which form the MCC slurry, fail to provide MCC with enhanced compressibility.
- the average particle size of the integrated excipient of the present invention ranges from about 10 microns to about 1000 microns Particle sizes of about 10- 500 microns are preferred, particle sizes of about 30-250 microns are more preferred and particle sizes of about 40-200 microns are most preferred It will be appreciated by those of ordinary skill in the art that the drying of the micro ⁇ crystalline cellulose-SLS suspension results in a random size distribution of the novel excipient particles being produced.
- the particle size of the integrated excipient is not narrowly critical, the important parameter being that the average size of the panicle must permit the formation of a directly compressible excipient which forms pharmaceutically acceptable tablets.
- the novel excipient has a bulk (loose) density ranging from about 0.2 g/ml to about 0.5 g/ml, and most preferably from about 0.22 g/ml to about 0.35 g/ml.
- the novel excipient has a tapped density ranging from about 0.30 g/ml to about 0.70 g/ml, and most preferably from about 0.35 g/ml to about 0.60 g/ml.
- the pH of the particles is most preferably about neutral, although granulates having a pH of from about 3.0 to about 8.5 are possible.
- the moisture content of the excipient particles will broadly range from about 0.5% to about 15%, preferably from about 2.5% to about 6%, and most preferably from about 3.0% to about 5% by weight.
- the novel excipient of the invention is free-flowing and directly compressible. Accordingly, the excipient may be mixed in the desired proportion with an active agent and optional lubricant (dry granulation), and then directly compressed into solid dosage forms.
- the novel excipient comprising the coprocessed microcrystalline cellulose and SLS integrated together represents an augmented microcrystalline cellulose having improved compressibility as compared to standard commercially available grades of microcrystalline cellulose.
- all or part of the excipient may be subjected to a wet granulation with the active ingredient.
- a representative wet granulation includes loading the novel excipient particles into a suitable granulator, such as those available from Baker-Perkins, and granulating the particles together with the active ingredient, preferably using an aqueous granulating liquid. The granulating liquid is added to the mixture with stirring until the powdery mass has the consistency of damp snow and then wet screened through a desired mesh screen, for example, having a mesh from about 12 to about 16.
- the screened granulate is then dried, using standard drying apparatus such as a convection oven before undergoing a final screenin Additional dry screening of this material is possible, such as by using screens of from about 40 to about 200 mesh. Those materials flowing through 40 and 60 mesh screens may be further ground prior to ultimate tablet formulation.
- standard drying apparatus such as a convection oven
- Additional dry screening of this material is possible, such as by using screens of from about 40 to about 200 mesh. Those materials flowing through 40 and 60 mesh screens may be further ground prior to ultimate tablet formulation.
- a portion of the total amount of the novel excipient is wet granulated with the active ingredient, and thereafter the additional portion of the novel excipient is added to the granulate.
- the additional portion of the novel excipient to be added to the excipient/active ingredient granulate may be substituted with conventional microcrystalline cellulose, or other excipients commonly used by those skilled in the art, depending of course upon the requirements of the particular formulation.
- the amount of the novel excipient compared to the amount of microcrystalline cellulose which must be used in a wet granulation technique to obtain an acceptable solid dosage form is substantially reduced.
- a further material is added to the slurry of microcrystalline cellulose and SLS.
- additional materials include silicon dioxides, non-silicon metal oxides, starches, starch derivatives, surfactants, polyalkylene oxides, cellulose ethers, celluloses esters and mixtures thereof. These additives may be included in desired amounts which will be apparent to those skilled in the art.
- MCC-based compositions which contain not only a surfactant but also from about
- the silicon dioxide utilized in this aspect of the invention is preferably of the very fine particle size variety.
- the silicon dioxide utilized is a colloidal silicon dioxide.
- Colloidal silicon dioxide is a submicron fumed silica prepared by the vapor-phase hydrolysis (e.g., at 1 1 10° C) of a silicon compound, such as silicon tetrachloride
- the product itself is a submicron, fluffy, light, loose, bluish-white, odorless and tasteless amoi ⁇ uous powder which is commercially available from a number of sources, including Cabot Corporation (under the tradename Cab-O-Sil); Degussa, Inc.
- colloidal silicon dioxide is also known as colloidal silica, fumed silica, light anhydrous silicic acid, silicic anhydride, and silicon dioxide fumed, among others.
- a variety of commercial grades of colloidal silicon dioxide are produced by varying the manufacturing process. These modifications do not affect the silica content, specific gravity, refractive index, color or amorphous form.
- the surface area of the preferred class of silicon dioxides utilized in the invention ranges from about 50 nr/gm to about 500 nr/gm.
- the average primary particle diameter of the preferred class of silicon dioxides utilized in the invention ranges from about 5 nm to about 50 nm. However, in commercial colloidal silicon dioxide products, these particles are agglomerated or aggregated to varying extents.
- the bulk density of the preferred class of silicon dioxides utilized in the invention ranges from about 20 g/l to about 100 g/1.
- colloidal silicon dioxide products have, for example, a BET surface area ranging from about 50 ⁇ 15 nr/gm (Aerosil OX50) to about 400 ⁇ 20 (Cab-O-Sil S-17) or 390 ⁇ 40 nr/gm (Cab-O-Sil EH-5).
- particle sizes range from a nominal particle diameter of 7 nm (e.g., Cab-O- Sil S-17 or Cab-O-Sil EH-5) to an average primary particle size of 40 nm (Aerosil OX50).
- the density of these products range from 72.0 ⁇ 8 g/l (Cab-O-Sil S-17) to
- any generally accepted soluble or insoluble inert pharmaceutical filler (diluent) material can be included in the final product (e.g., a solid dosage form).
- the inert pharmaceutical filler comprises a monosaccharide, a disaccharide, a polyhydric alcohol, inorganic phosphates, sulfates or carbonates, and/or mixtures thereof.
- suitable inert pharmaceutical fillers include sucrose, dextrose, lactose, xylitol, fructose, sorbitol, calcium phosphate, calcium sulfate, calcium carbonate, "off-the-shelf microcrystalline cellulose, mixtures thereof, and the like.
- an effective amount of any generally accepted pharmaceutical lubricant, including the calcium or magnesium soaps may optionally be added to the novel excipient at the time the medicament is added, or in any event prior to compression into a solid dosage form.
- the lubricant may comprise, for example, magnesium stearate in any amount of about 0.5-3% by weight of the solid dosage form.
- the complete mixture in an amount sufficient to make a uniform batch of tablets, may then subjected to tabletting in a conventional production scale tabletting machine at normal compression pressures for that machine, e.g., about
- the average tablet size for round tablets is preferably about 50 mg to 500 mg and for capsule-shaped tablets about 200 mg to 2000 mg.
- other formulations prepared in accordance with the present invention may be suitably shaped for other uses or locations, such as other bodv cavities, e.g., periodontal pockets, surgical wounds, vaginally. It is contemplated that for certain uses, e.g., antacid tablets, vaginal tablets and possibly implants, that the tablet will be larger
- the tablet is coated with a sufficient amount of a hydrophobic polymer to render the formulation capable of providing a release of the medicament such that a 12 or 24 hour formulation is obtained.
- the hydrophobic polymer which included in the tablet coating may be the same or different material as compared to the hydrophobic polymeric material which is optionally granulated with the sustained release excipient.
- the tablet coating may comprise an enteric coating material in addition to or instead or the hydrophobic polymer coating.
- enteric polymers examples include cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate, methacrylic acid copolymer, shellac, hydroxypropylmethylcellulose succinate, cellulose acetate trimellitate, and mixtures of any of the foregoing.
- enteric material is available under the trade name EudragitTM L 100-555.
- the dosage form may be coated with a hydrophilic coating in addition to or instead of the above-mentioned coatings.
- a hydrophilic coating is hydroxy ⁇ propylmethylcellulose (e.g., Opadry®, commercially available from Colorcon, West Point, Pennsylvania).
- the coatings may be applied in any pharmaceutically acceptable manner known to those skilled in the art.
- the coating is applied via a fluidized bed or in a coating pan.
- the coated tablets may be dried, e.g., at about 60-70° C for about 3-4 hours in a coating pan.
- the solvent for the hydrophobic polymer or enteric coating may be organic, aqueous, or a mixture of an organic and an aqueous solvent.
- the organic solvents may be, e.g., isopropyl alcohol, ethanol, and the like, with or without water.
- the coatings which may be optionally applied to the compressed solid dosage form of the invention may comprise from about 0.5% to about 30% by weight of the final solid dosage form.
- a support platform is applied to the tablets manufactured in accordance with the present invention.
- Suitable support platforms are well known to those skilled in the art.
- An example of suitable support platforms is set forth, e.g., in U.S. Patent No. 4,839, 177, hereby incorporated by reference.
- the support platform partially coats the tablet, and consists of a polymeric material insoluble in aqueous liquids.
- the support platform may, for example, be designed to maintain its impermeability characteristics during the transfer of the therapeutically active medicament.
- the support platform may be applied to the tablets, e.g., via compression coating onto part of the tablet surface, by spray coating the polymeric materials comprising the support platform onto all or part of the tablet surface, or by immersing the tablets in a solution of the polymeric materials.
- the support platform may have a thickness of, e.g., about 2 mm if applied by compression, and about 10 ⁇ m if applied via spray-coating or immersion- coating.
- a hydrophobic polymer or enteric coating is applied to the tablets, the tablets are coated to a weight gain from about 1% to about 20%, and in certain embodiments preferably from about 5% to about 10%.
- Materia useful in the hydrophobic coatings and support platforms of the present invention include derivatives of acrylic acid (such as esters of acrylic acid, methacrylic acid, and copolymers thereof) celluloses and derivatives thereof (such as ethylcellulose), polyvinyl alcohols, and the like.
- acrylic acid such as esters of acrylic acid, methacrylic acid, and copolymers thereof
- celluloses and derivatives thereof such as ethylcellulose
- polyvinyl alcohols and the like.
- the tablet core includes an additional dose of the medicament included in either the hydrophobic or enteric coating, or in an additional overcoating coated on the outer surface of the tablet core (without the hydrophobic or enteric coating) or as a second coating layer coated on the surface of the base coating comprising the hydrophobic or enteric coating material
- a loading dose of a therapeutically active agent is needed to provide therapeutically effective blood levels of the active agent when the formulation is first exposed to gastric fluid.
- the loading dose of medicament included in the coating layer may be, e g , from about 10% to about 40% of the total amount of medicament included in the formulation.
- the active agent(s) which may be incorporated with the novel excipient described herein into solid dosage forms invention include systemically active thera ⁇ Chamberic agents, locally active therapeutic agents, disinfecting agents, chemical impregnants, cleansing agents, deodorants, fragrances, dyes, animal repellents, insect repellents, fertilizing agents, pesticides, herbicides, fungicides, and plant growth stimulants, and the like.
- therapeutically active agents can be used in conjunction with the present invention.
- the therapeutically active agents e.g. pharmaceutical agents
- the therapeutically active agents include both water soluble and water insoluble drugs.
- examples of such therapeutically active agents include antihistamines (e.g., dimenhydrinate, diphenhydramine, chlor- pheniramine and dexchlorpheniramine maleate), analgesics (e.g., aspirin, codeine, morphine, dihydromorphone, oxycodone, etc.), non-steroidai anti-inflammatory agents (e.g., naproxyn, diclofenac, indomethacin, ibuprofen, sulindac), anti-emetics
- antihistamines e.g., dimenhydrinate, diphenhydramine, chlor- pheniramine and dexchlorpheniramine maleate
- analgesics e.g., aspirin, codeine, morphine, dihydromorphone
- vasodilators e.g., nifedipine, papaverine, diltiazem and nicardirine
- anti-tussive agents and expectorants e.g., codeine phosphate
- anti-asthmatics e.g. theophylline
- antacids e.g. theophylline
- anti-spasmodics e.g. atropine, scopolamine
- antidiabetics e.g., insulin
- diuretics e.g., ethacrynic acid, bendrofluazide
- anti-hypotensives e.g., metoclopramide
- anti-epileptics e.g., phenytoin, meprobamate and nitrazepam
- vasodilators e.g., nifedipine, papaverine, diltiazem and nicardirine
- bronchodilators e.g., albuterol
- steroids e.g., hydrocortisone, triamcinolone, prednisone
- antibiotics e.g., tetracycline
- antihemorrhoidals hypnotics, psycho- tropics, antidiarrheals, mucolytics, sedatives, decongestants, laxatives, vitamins, stimulants (including appetite suppressants such as phenylpropanolamine).
- appetite suppressants such as phenylpropanolamine
- locally active agents can be used in conjunction with the novel excipient described herein, and include both water soluble and water insoluble agents
- the locally active agent(s) which may be included in the controlled release formulation of the present invention is intended to exert its effect in the environment of use, e.g., the oral cavity, although in some instances the active agent may also have systemic activity via absorption into the blood via the surrounding mucosa.
- the locally active agent(s) include antifungal agents (e.g., amphotericin B, clotrimazole, nystatin, ketoconazole, miconazol, etc.), antibiotic agents (penicillins, cephalosporins, erythromycin, tetracycline, aminoglycosides, etc.), antiviral agents (e g, acyclovir, idoxuridine, etc.), breath fresheners (e.g.
- antitussive agents e.g., dextromethorphan hydrochloride
- anti-cariogenic compounds e.g., metallic salts of fluoride, sodium monofluorophosphate, stannous fluoride, amine fluorides
- analgesic agents e.g., methylsalicylate, salicylic acid, etc.
- local anesthetics e.g., benzocaine
- oral antiseptics e.g., chlorhexidine and salts thereof, hexylresorcinol, dequalinium chloride, cetylpyridinium chloride
- anti-inflammatory agents e.g., dexamethasone, betamethasone, prednisone, prednisolone, triam- cinolone, hydrocortisone, etc.
- hormonal agents oestriol
- antiplaque agents e.g, chlorhexidine and salts thereof, octenidine, and mixtures of thymol,
- the solid formulations of the invention may also include other locally active agents, such as flavorants and sweeteners. Generally any flavoring or food additive such as those described in Chemicals Used in Food Processing, pub 1274 by the National Academy of Sciences, pages 63-258 may be used. Generally, the final product may include from about 0.1% to about 5% by weight flavorant.
- the tablets of the present invention may also contain effective amounts of coloring agents, (e.g., titanium dioxide, F.D. &. C. and D & C. dyes; see the Kirk- Oth er Encyclopedia of Chemical Technology, Vol. 5, pp.
- the novel excipient can be utilized in other applications wherein it is not compressed.
- the granulate can be admixed with an active ingredient and the mixture then filled into capsules.
- the granulate can further be molded into shapes other than those typically associated with tablets.
- the granulate together with active ingredient can be molded to "fit" into a particular area in an environment of use (e.g., an implant). All such uses would be contemplated by those skilled in the art and are deemed to be encompassed within the scope of the appended claims.
- the examples set forth the preparation of various microcrystalline cellulose/ anionic surfactant compositions. Tablets were prepared using each of the compositions and each of tablet preparations was tested for tensile strength.
- EXAMPLE 1 MCC-SLS Product - 0.25% w/w SLS A.
- EXCIPIENT PARTICLES In this example, about 6.2 kilograms of microcrystalline cellulose (MCC),
- the slurry was allowed to mix for about 15 minutes before being combined with 0.25% w/w sodium lauryl sulfate (SLS) powder (available from Spectrum Chemical, Gardena, CA.) After allowing the materials to become intimately combined, the slurry was spray dried using a Niro Production Minor (Niro, Columbia, MD), inlet temperature-215°C, outlet temperature- 125 °C, atomizer wheel speed 22,300 rpm, to provide MCC-SLS having an average particle size of 40-60 microns.
- SLS sodium lauryl sulfate
- the MCC-SLS particles obtained as a result of step 1 A. were wet granulated in a Baker-Perkins 10 liter high-sheer granulator for 3 minutes using water as the granulating fluid.
- the resultant product was wet screened through a 12 mesh screen, tray dried in a convection oven for about 2-3 hours until a moisture content of less than 5% was obtained, dry screened and sieved to obtain an average particle size of from about 55 to about 70 microns.
- Example 1 A and B The processes of Example 1 A and B were repeated except that 0.5% w/w sodium lauryl sulfate was used to form the product of Example 2; 0.1% w/w SLS was used to fonn the product of Example 3; 0.2% w/w SLS was used to form the product of Example 4; and 0.3% w/w SLS was used to form the product of Example 5.
- EMCOCEL® grade 50 M microcrystalline cellulose (Mendell Co., Inc.) and 0.25% w/w SLS powder were dry blended. No spray drying or other treatment of the mixture was undertaken. The method of Example 1 B, however, was repeated.
- EXAMPLE 7 Processed MCC without SLS
- Example IB As a second control, the process described in Example IB was repeated except that no SLS was added.
- batches of compressed tablets were prepared using each of the products obtained as a result of Examples 1-7.
- the tablets were prepared using a Korsch tablet press having a punch size of 3/8" and an aim weight of about 245 mg.
- the granulations were included in five separate tabletting runs using compression forces of 6, 12, 18, 24 and 30 kN respectively.
- Ten tablets from each run were weighed, measured for diameter and tested for thickness and hardness on the Erweka TBH 30 tablet hardness tester to determine the compressibility of the microcrystalline cellulose as measured by tensile strength.
- the results of the analysis for the products of Examples 1 , 3-7 are graphically illustrated in Figure 1 as a comparison of tensile strength versus compression force.
- the results obtained using the product of Example 2 were determined to be comparable to that obtained for the product of Example 3 (0.1% SLS).
- Example 1 A the coprocessing method described in Example 1 A was repeated except that docusate sodium (Spectrum Chemical) was used as the coprocessing agent).
- docusate sodium Spectrum Chemical
- Example I B The resultant granulates prepared according to Example I B were tabletted according to the same method described in Example 8 and evaluated for tensile strength.
- inventive Example 4 MCC-SLS 0.20%w/w
- Example 7 MCC alone
- Example 1 A the coprocessing method described in Example 1 A was repeated using the non-ionic surfactant polysorbate 40 (Spectrum Chemical) as the coprocessing agent.
- Example Polysorbate 40 (wt %)
- Example I B The resultant granulates prepared according to Example I B were tabletted according to the same method described in Example 8 and evaluated for tensile strength.
- inventive Example 4 MCC-SLS 0.2%w/w
- Example 7 MCC alone
- the coprocessing method described in example 1 was repeated using simethicone (Dow Corning, Midland. MI.) as the surfactant coprocessing agent.
- Example 17 2.0 The resultant granulates prepared according to Example IB were tabletted according to the same method described in Example 8 and evaluated for tensile strength.
- this surfactant provides little, if any, improvement in the retention of MCC compressibility. It can, therefore, be seen that mere addition of any lubricant in any amount is not sufficient to allow MCC to retain its compressibility in wet granulations. Rather, selected surfactants, present within the claimed ranges, provide the desirable compressibility characteristics to the
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP52234796A JP3728321B2 (en) | 1995-01-09 | 1996-01-05 | Pharmaceutical excipients with improved compressibility |
AT96907007T ATE445391T1 (en) | 1995-01-09 | 1996-01-05 | PHARMACEUTICAL CARRIER WITH IMPROVED PRESSABILITY |
CA002183882A CA2183882C (en) | 1995-01-09 | 1996-01-05 | Pharmaceutical excipient having improved compressibility |
DE69638054T DE69638054D1 (en) | 1995-01-09 | 1996-01-05 | PHARMACEUTIC CARRIER WITH IMPROVED COMPRESSABILITY |
KR1019960704934A KR100332337B1 (en) | 1995-01-09 | 1996-01-05 | Highly compressible drug excipient |
EP96907007A EP0749300B1 (en) | 1995-01-09 | 1996-01-05 | Pharmaceutical excipient having improved compressibility |
AU50199/96A AU708346B2 (en) | 1995-01-09 | 1996-01-05 | Pharmaceutical excipient having improved compressibility |
BR9605245A BR9605245A (en) | 1995-01-09 | 1996-01-05 | Excipient composition aqueous paste to prepare from a compressible pharmaceutical excipient solid dosage form to increase microcrystalline cellulose compressibility in wet granulation products particulate excipient to prepare solid dosage form and microcrystalline cellulose excipient |
MXPA/A/1996/003746A MXPA96003746A (en) | 1995-01-09 | 1996-08-29 | Pharmaceutical excipient that has compressibility best |
NO19963733A NO321771B1 (en) | 1995-01-09 | 1996-09-06 | Excipient composition, aqueous slurry composition and process for preparing an excipient. |
FI963496A FI963496A (en) | 1995-01-09 | 1996-09-06 | Pharmaceutical excipient with better compressibility |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/370,576 | 1995-01-09 | ||
US08/370,576 US5585115A (en) | 1995-01-09 | 1995-01-09 | Pharmaceutical excipient having improved compressability |
US08/486,183 US5725883A (en) | 1995-01-09 | 1995-06-07 | Pharmaceutical excipient having improved compressibility |
US08/486,183 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996022080A1 true WO1996022080A1 (en) | 1996-07-25 |
Family
ID=27005010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/000539 WO1996022080A1 (en) | 1995-01-09 | 1996-01-05 | Pharmaceutical excipient having improved compressibility |
Country Status (12)
Country | Link |
---|---|
US (3) | US5866166A (en) |
EP (1) | EP0749300B1 (en) |
JP (1) | JP3728321B2 (en) |
AU (1) | AU708346B2 (en) |
BR (1) | BR9605245A (en) |
CA (1) | CA2183882C (en) |
FI (1) | FI963496A (en) |
HU (1) | HUP9602361A3 (en) |
IL (3) | IL116674A (en) |
NO (1) | NO321771B1 (en) |
TW (1) | TW505529B (en) |
WO (1) | WO1996022080A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2761266A1 (en) * | 1997-03-28 | 1998-10-02 | Sanofi Sa | WET-GRANULATED PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF AN N-PIPERIDINO-3-PYRAZOLECARBOXAMIDE DERIVATIVE, ITS SALTS AND SOLVATES |
WO1999061037A1 (en) * | 1998-05-22 | 1999-12-02 | Amway Corporation | Plant material composition |
WO2000077088A1 (en) * | 1999-06-14 | 2000-12-21 | Centre National De La Recherche Scientifique | Microfibrillated and/or microcrystalline dispersion, in particular of cellulose, in an organic solvent |
US20050051922A1 (en) * | 2002-09-20 | 2005-03-10 | Avinash Nangia | Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same |
Families Citing this family (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440457B1 (en) * | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US6395303B1 (en) * | 1996-06-10 | 2002-05-28 | Edward Mendell Co., Inc. | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose |
US6106865A (en) * | 1995-01-09 | 2000-08-22 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
US6936277B2 (en) * | 1995-01-09 | 2005-08-30 | J. Rettenmaier & Soehne Gmbh & Co. Kg | Pharmaceutical excipient having improved compressibility |
US5948438A (en) * | 1995-01-09 | 1999-09-07 | Edward Mendell Co., Inc. | Pharmaceutical formulations having improved disintegration and/or absorptivity |
DE29502547U1 (en) * | 1995-02-16 | 1995-03-30 | Roehm Gmbh | Thermoplastic coating and binding agent for pharmaceutical forms |
US20030109503A1 (en) * | 1995-06-06 | 2003-06-12 | Smithkline Beecham P.L.C. | Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics |
ATE283038T1 (en) * | 1995-07-21 | 2004-12-15 | Daiichi Seiyaku Co | METHOD FOR PRODUCING A GRANULAR PREPARATION |
TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
SE9604124D0 (en) * | 1996-11-12 | 1996-11-12 | Pharmacia & Upjohn Ab | Compact member, method of manufacturing and use thereof |
US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
US6531154B1 (en) * | 1997-06-10 | 2003-03-11 | Brown University Research Foundation | Modulated release from biocompatible polymers |
NZ328751A (en) * | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
IN186245B (en) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
US6066339A (en) * | 1997-10-17 | 2000-05-23 | Elan Corporation, Plc | Oral morphine multiparticulate formulation |
GB9724186D0 (en) | 1997-11-14 | 1998-01-14 | British Tech Group | Low temperature coatings |
DE69812094T2 (en) * | 1997-12-22 | 2003-12-24 | Schering Corp | SOLID, ORAL ADMINISTRATIVE RIBAVIRIN DOSE FORMS AND METHOD FOR THE PRODUCTION THEREOF |
CN1173742C (en) * | 1997-12-26 | 2004-11-03 | 山之内制药株式会社 | Sustained release medicinal compositions |
JP4533531B2 (en) * | 1998-04-03 | 2010-09-01 | ビーエム リサーチ エイ/エス | Controlled release composition |
US6992066B2 (en) * | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
US7087577B2 (en) * | 1998-10-16 | 2006-08-08 | Zimmer Orthobiologies, Inc. | Method of promoting natural bypass |
US6416786B1 (en) | 1998-12-11 | 2002-07-09 | Nostrum Pharmaceuticals, Inc. | Sustained release tablet containing hydrocolloid and cellulose ether |
US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
US6586023B1 (en) | 1998-12-15 | 2003-07-01 | Wm. Wrigley Jr. Company | Process for controlling release of active agents from a chewing gum coating and product thereof |
US6627234B1 (en) | 1998-12-15 | 2003-09-30 | Wm. Wrigley Jr. Company | Method of producing active agent coated chewing gum products |
US7163705B2 (en) * | 1998-12-15 | 2007-01-16 | Wm. Wrigley Jr. Company | Coated chewing gum product and method of making |
DE19913606A1 (en) * | 1999-03-25 | 2000-09-28 | Basf Ag | Powdery solubilization aids for solid pharmaceutical dosage forms |
IT1305308B1 (en) * | 1999-03-26 | 2001-05-04 | Biosint S P A | HIGH-CONTENT GRANULATE OF L-CARNITINE OR ALCANOYL-L-CARNITINE, PARTICULARLY SUITABLE FOR THE PRODUCTION OF COMPRESSION TABS |
US6426090B1 (en) * | 1999-04-06 | 2002-07-30 | Wm. Wrigley Jr. Company | Over-coated product including tableted center and medicament |
US6355265B1 (en) | 1999-04-06 | 2002-03-12 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
US6322806B1 (en) | 1999-04-06 | 2001-11-27 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations including tableted center |
AU784112B2 (en) * | 1999-04-06 | 2006-02-09 | Wm. Wrigley Jr. Company | Pharmaceutical chewing gum formulations |
US7935362B2 (en) * | 1999-04-06 | 2011-05-03 | Wm. Wrigley Jr. Company | Over-coated product including consumable center and medicament |
US6773716B2 (en) | 1999-04-06 | 2004-08-10 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
US20020159956A1 (en) * | 1999-04-06 | 2002-10-31 | Ream Ronald L. | Over-coated chewing gum formulations |
US7250176B1 (en) * | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
US8895064B2 (en) | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
AU5680100A (en) | 1999-06-14 | 2001-01-02 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
US20040258750A1 (en) * | 1999-06-28 | 2004-12-23 | Gerard Alaux | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
US6264973B1 (en) * | 1999-08-26 | 2001-07-24 | Fei Enterprises, Ltd. | Apparatus and method for anesthetizing the cervical region of a female |
US6663849B1 (en) | 2000-09-01 | 2003-12-16 | Wm. Wrigley Jr. Company | Antacid chewing gum products coated with high viscosity materials |
US6569472B1 (en) | 2000-09-01 | 2003-05-27 | Wm. Wrigley Jr. Company | Coated chewing gum products containing antacid and method of making |
US6541048B2 (en) | 1999-09-02 | 2003-04-01 | Wm. Wrigley Jr. Company | Coated chewing gum products containing an acid blocker and process of preparing |
US6645535B2 (en) | 1999-09-02 | 2003-11-11 | Wm. Wrigley Jr. Company | Method of making coated chewing gum products containing various antacids |
AU3885201A (en) * | 1999-09-20 | 2001-04-24 | Mastercare | Diet and weight control gum and sucker |
US9387168B2 (en) | 1999-09-20 | 2016-07-12 | Jack Barreca | Chewing gum with tomatidine |
US9253991B2 (en) | 1999-09-20 | 2016-02-09 | Jack Barreca | Chewing gum with B vitamins |
GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
EP2295043A1 (en) | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
US6660303B2 (en) * | 1999-12-06 | 2003-12-09 | Edward Mendell & Co. | Pharmaceutical superdisintegrant |
DK1241949T3 (en) * | 1999-12-30 | 2012-07-30 | Wrigley W M Jun Co | RELEASE OF LIPOFILE ACTIVE SUBSTANCES FROM CHEMICAL GUM |
US6350480B1 (en) | 1999-12-30 | 2002-02-26 | Wm. Wrigley Jr. Company | Chewing gum product including a hydrophilic gum base and method of producing |
US6399101B1 (en) | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
AUPQ672800A0 (en) * | 2000-04-06 | 2000-05-04 | Natraherbal Pty Ltd | Garlic supplement for deodoriser |
WO2001091730A1 (en) * | 2000-05-31 | 2001-12-06 | Drugtech Corporation | Mineral supplement |
US6572900B1 (en) | 2000-06-09 | 2003-06-03 | Wm. Wrigley, Jr. Company | Method for making coated chewing gum products including a high-intensity sweetener |
US7115288B2 (en) * | 2000-06-09 | 2006-10-03 | Wm. Wrigley Jr. Company | Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener |
US6358526B1 (en) * | 2000-08-16 | 2002-03-19 | Rexall Sundown | Method of making tablets and tablet compositions produced therefrom |
US6444241B1 (en) | 2000-08-30 | 2002-09-03 | Wm. Wrigley Jr. Company | Caffeine coated chewing gum product and process of making |
EP1330236A2 (en) | 2000-10-12 | 2003-07-30 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
CN101317825A (en) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | Controlled release hydrocodone formulations |
US6887492B2 (en) | 2000-12-14 | 2005-05-03 | Leiner Health Services Corp. | Magnesium plus interactive agent delivery |
US6579545B2 (en) | 2000-12-22 | 2003-06-17 | Wm. Wrigley Jr. Company | Coated chewing gum products containing an antigas agent |
US6416752B1 (en) * | 2001-01-04 | 2002-07-09 | Whitmire Micro-Gen Research Laboratories, Inc. | Termite bait composition and method |
CA2440588C (en) * | 2001-03-13 | 2010-02-09 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
WO2003020241A2 (en) * | 2001-09-05 | 2003-03-13 | Vectura Limited | Functional powders for oral delivery |
US20040253310A1 (en) * | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
PE20030527A1 (en) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT |
US6753017B2 (en) * | 2001-11-07 | 2004-06-22 | Jrs Pharma Lp | Process for preparing dry extracts |
US20030099699A1 (en) * | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
US6645526B2 (en) * | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
US20030206978A1 (en) * | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
US7179488B2 (en) * | 2001-11-29 | 2007-02-20 | Bob Sherwood | Process for co-spray drying liquid herbal extracts with dry silicified MCC |
US6958161B2 (en) * | 2002-04-12 | 2005-10-25 | F H Faulding & Co Limited | Modified release coated drug preparation |
US7125563B2 (en) * | 2002-04-12 | 2006-10-24 | Dava Pharmaceuticals, Inc. | Sustained release pharmaceutical preparations and methods for producing the same |
WO2003096976A2 (en) | 2002-05-14 | 2003-11-27 | Fmc Corporation | Microcrystalline cewllulose compositions |
US20040001885A1 (en) * | 2002-06-27 | 2004-01-01 | Unchalee Kositprapa | Rapidly disintegrating antihistamine formulation |
US20050020613A1 (en) * | 2002-09-20 | 2005-01-27 | Alpharma, Inc. | Sustained release opioid formulations and method of use |
RU2336703C2 (en) * | 2002-09-26 | 2008-10-27 | Касематик, С.А. Де С.В. | Casing for food products (versions), methods of casing manufacture and enhancement of casing removal from cooked sausage |
US20040062778A1 (en) * | 2002-09-26 | 2004-04-01 | Adi Shefer | Surface dissolution and/or bulk erosion controlled release compositions and devices |
US20040151772A1 (en) * | 2002-11-08 | 2004-08-05 | Egalet A/S | Controlled release carvedilol compositions |
US20040161459A1 (en) * | 2002-12-31 | 2004-08-19 | Ngoc Do | Fast-dissolve tablet technology |
ES2360102T3 (en) | 2003-03-26 | 2011-05-31 | Egalet A/S | SYSTEM FOR CONTROLLED RELEASE OF MORPHINE. |
DE602004025159D1 (en) * | 2003-03-26 | 2010-03-04 | Egalet As | Matrix preparations for the controlled administration of drugs |
GB0310673D0 (en) | 2003-05-09 | 2003-06-11 | Givaudan Sa | Alginate matrix particles |
US20060165790A1 (en) * | 2003-06-27 | 2006-07-27 | Malcolm Walden | Multiparticulates |
US20050118267A1 (en) * | 2003-09-19 | 2005-06-02 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
WO2005027878A1 (en) * | 2003-09-19 | 2005-03-31 | Penwest Pharmaceuticals Co. | Delayed released dosage forms |
CA2543458A1 (en) * | 2003-10-24 | 2005-05-12 | Josef Rettenmaier & Soehne Gmbh & Co., Kg | Process for co-spray drying agents with dry silicified mcc |
US8591972B2 (en) | 2005-05-23 | 2013-11-26 | Kraft Foods Global Brands Llc | Delivery system for coated active components as part of an edible composition |
US8597703B2 (en) | 2005-05-23 | 2013-12-03 | Kraft Foods Global Brands Llc | Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component |
US20050112236A1 (en) | 2003-11-21 | 2005-05-26 | Navroz Boghani | Delivery system for active components as part of an edible composition having preselected tensile strength |
US8591973B2 (en) | 2005-05-23 | 2013-11-26 | Kraft Foods Global Brands Llc | Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition |
US8389032B2 (en) * | 2005-05-23 | 2013-03-05 | Kraft Foods Global Brands Llc | Delivery system for active components as part of an edible composition having selected particle size |
US8389031B2 (en) * | 2005-05-23 | 2013-03-05 | Kraft Foods Global Brands Llc | Coated delivery system for active components as part of an edible composition |
US8591968B2 (en) | 2005-05-23 | 2013-11-26 | Kraft Foods Global Brands Llc | Edible composition including a delivery system for active components |
US7201920B2 (en) * | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
EP1566173B1 (en) * | 2004-02-20 | 2006-08-16 | Mattern, Udo | Pharmaceutical composition for oral application and method for preparing thereof |
US20050220877A1 (en) * | 2004-03-31 | 2005-10-06 | Patel Ashish A | Bilayer tablet comprising an antihistamine and a decongestant |
HUE037643T2 (en) | 2004-06-12 | 2018-09-28 | Collegium Pharmaceutical Inc | Abuse-deterrent drug formulations |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
US20060068010A1 (en) * | 2004-09-30 | 2006-03-30 | Stephen Turner | Method for improving the bioavailability of orally delivered therapeutics |
KR20070072888A (en) * | 2004-10-25 | 2007-07-06 | 니뽄 다바코 산교 가부시키가이샤 | Solid medicinal preparation improved in solubility and stability and process for producing the same |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20070231268A1 (en) * | 2004-11-24 | 2007-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
ES2537974T3 (en) | 2004-11-26 | 2015-06-16 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for the treatment of hepatic encephalopathy |
CA2611081C (en) * | 2005-06-03 | 2016-05-31 | Egalet A/S | A drug delivery system for delivering active substances dispersed in a dispersion medium |
WO2007014124A2 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
US7879382B2 (en) * | 2005-09-30 | 2011-02-01 | Fmc Corporation | Stabilizers and compositions and products comprising same |
JP2009537553A (en) | 2006-05-19 | 2009-10-29 | ソマクソン ファーマシューティカルズ インコーポレイテッド | Use of low-dose doxepin to improve sleep |
US20100179215A1 (en) | 2006-05-19 | 2010-07-15 | Somaxon Pharmaceuticals, Inc. | Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders |
US20100179214A1 (en) | 2006-05-19 | 2010-07-15 | Somaxon Pharmaceuticals, Inc. | Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders |
WO2007136845A2 (en) | 2006-05-19 | 2007-11-29 | Somaxon Pharmaceuticals, Inc. | Low-dose doxepin for treatment of sleep disorders in elderly patients |
WO2007136741A2 (en) * | 2006-05-19 | 2007-11-29 | Somaxon Pharmaceuticals, Inc. | N-desmethyl-doxepin and methods of using the same to treat sleep disorders |
US20070281016A1 (en) * | 2006-06-06 | 2007-12-06 | Endo Pharmaceuticals Inc., A Delaware Corporation | Sustained release oxycodone composition with acrylic polymer and surfactant |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
CA2693992C (en) | 2006-07-20 | 2017-01-31 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
US7538652B2 (en) * | 2006-08-29 | 2009-05-26 | International Business Machines Corporation | Electrical component tuned by conductive layer deletion |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
WO2008039358A2 (en) * | 2006-09-30 | 2008-04-03 | Capricorn Pharma Inc. | Resin-complex granulation for water-soluble drugs and associated methods |
WO2008085567A1 (en) * | 2006-10-04 | 2008-07-17 | Somaxon Pharmaceuticals, Inc. | Methods of using low-dose doxepin for the improvement of sleep |
US20100105614A1 (en) | 2006-10-25 | 2010-04-29 | Somaxon Pharmaceuticals, Inc. | Ultra low dose doxepin and methods of using the same to treat sleep disorders |
DE602007011792D1 (en) * | 2006-10-27 | 2011-02-17 | Fmc Corp | COMMONLY PREPARED MICROCRYSTALLINE CELLULOSE AND SUGAR ALCOHOL AS AN AUXILIARY FOR TABLET FORMULATIONS |
WO2008070795A2 (en) | 2006-12-06 | 2008-06-12 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
NZ577560A (en) * | 2007-01-16 | 2012-01-12 | Egalet Ltd | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
CA2721133C (en) | 2007-04-13 | 2018-11-06 | Somaxon Pharmaceuticals, Inc. | Low-dose doxepin formulations and methods of making and using the same |
US20080268036A1 (en) * | 2007-04-24 | 2008-10-30 | Jrs Pharma | Co-processing of active pharmaceutical/nutraceutical ingredients |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
EP2200613B1 (en) | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
US20100055180A1 (en) * | 2007-10-10 | 2010-03-04 | Mallinckrodt Baker, Inc. | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof |
KR101633939B1 (en) * | 2007-10-10 | 2016-06-27 | 아반토르 퍼포먼스 머티리얼스, 인크. | Directly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof |
US20090181390A1 (en) * | 2008-01-11 | 2009-07-16 | Signosis, Inc. A California Corporation | High throughput detection of micrornas and use for disease diagnosis |
AU2009202778B2 (en) * | 2008-07-11 | 2014-05-08 | Commonwealth Of Australia As Represented By And Acting Through The Department Of The Environment, Water, Heritage And The Arts | Improved baiting method and composition |
US20100094075A1 (en) * | 2008-10-10 | 2010-04-15 | Hologic Inc. | Expandable medical devices with reinforced elastomeric members and methods employing the same |
NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
CA3205755A1 (en) | 2009-04-03 | 2010-10-07 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
US20100285164A1 (en) * | 2009-05-11 | 2010-11-11 | Jrs Pharma | Orally Disintegrating Excipient |
JP5749255B2 (en) | 2009-06-08 | 2015-07-15 | ユーシーエル ビジネス ピーエルシー | Treatment of portal hypertension and repair of liver function using L-ornithine phenylacetate |
EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
AU2010300641B2 (en) * | 2009-09-30 | 2016-03-17 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
CA2779750C (en) | 2009-11-06 | 2019-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive diagnosis of graft rejection in organ transplant patients |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
MX2012012991A (en) | 2010-05-11 | 2012-11-30 | Cima Labs Inc | Alcoholres i stant metoprolol - containing extended - release oral dosage forms. |
JP5759457B2 (en) | 2010-06-29 | 2015-08-05 | 旭化成ケミカルズ株式会社 | Composite particles containing cellulose and inorganic compounds |
ES2643291T3 (en) | 2010-12-22 | 2017-11-22 | Purdue Pharma L.P. | Controlled release dosage forms with inviolable closure coated |
CA2822769C (en) | 2010-12-23 | 2016-10-04 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
US9365897B2 (en) | 2011-02-08 | 2016-06-14 | Illumina, Inc. | Selective enrichment of nucleic acids |
RU2559406C2 (en) | 2011-04-29 | 2015-08-10 | ИНТЕРКОНТИНЕНТАЛ ГРЕЙТ БРЭНДЗ ЭлЭлСи | Encapsulated acid, its production and chewing gum composition containing such acid |
US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
WO2013043922A1 (en) | 2011-09-22 | 2013-03-28 | ImmuMetrix, LLC | Compositions and methods for analyzing heterogeneous samples |
CN103842425B (en) | 2011-10-05 | 2017-05-24 | Fmc有限公司 | Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses |
ES2657648T3 (en) | 2011-10-05 | 2018-03-06 | Fmc Corporation | Stabilizing composition of microcrystalline cellulose and co-reduced carboxymethylcellulose, method for making it and uses |
PL2787837T3 (en) | 2011-12-09 | 2017-09-29 | Fmc Corporation | Co-attrited stabilizer composition |
GB201202433D0 (en) * | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
EP2877161A1 (en) | 2012-07-06 | 2015-06-03 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
US9101636B2 (en) | 2012-11-30 | 2015-08-11 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
KR101840526B1 (en) | 2013-02-05 | 2018-03-20 | 퍼듀 퍼머 엘피 | Tamper resistant pharmaceutical formulations |
DK3327123T3 (en) | 2013-03-15 | 2019-11-25 | Lineage Biosciences Inc | METHODS FOR SEQUENCING THE IMMUN REPERTOIR |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
ITBO20130126A1 (en) * | 2013-03-25 | 2014-09-26 | Naturalia Ingredients S R L | COMPRESSED INCLUDING FRUCTOSE |
AU2015237723B2 (en) | 2014-03-26 | 2018-04-26 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release biphasic matrix solid dosage form |
MX2017006685A (en) | 2014-11-24 | 2018-01-15 | Ucl Business Plc | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies. |
DK3285756T3 (en) * | 2015-04-20 | 2023-05-08 | Ocera Therapeutics Inc | FORMULATIONS OF L-ORNITHINE PHENYL ACETATE |
US10166185B2 (en) | 2015-06-09 | 2019-01-01 | J. Rettenmaier & Söhne Gmbh + Co Kg | Excipient and oral solid dosage forms for oily drugs |
AU2016308641B2 (en) | 2015-08-18 | 2022-02-03 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
WO2017040607A1 (en) | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
CN106822007B (en) | 2015-09-11 | 2021-12-31 | 西姆莱斯股份公司 | Oral preparation |
US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
EP3621947A4 (en) | 2017-05-11 | 2021-03-10 | Ocera Therapeutics, Inc. | Processes of making l-ornithine phenylacetate |
US11925707B2 (en) | 2021-03-15 | 2024-03-12 | Jrs Pharma Gmbh & Co. Kg | Co-processed lubricant:MCG for tablets |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4744987A (en) * | 1985-03-08 | 1988-05-17 | Fmc Corporation | Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation |
US4946685A (en) * | 1987-04-06 | 1990-08-07 | Alza Corporation | Cellulosic dosage form |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3023104A (en) * | 1960-07-05 | 1962-02-27 | American Viscose Corp | Food compositions incorporating cellulose crystallite aggregates |
US3067037A (en) * | 1960-12-02 | 1962-12-04 | American Viscose Corp | Foamable products containing disintegrated cellulose crystallite aggregates |
US3141875A (en) * | 1961-03-15 | 1964-07-21 | Fmc Corp | Crystallite aggregates disintegrated in acid medium |
US3573058A (en) * | 1967-01-30 | 1971-03-30 | Swift & Co | Microcrystalline cellulose compositions co-dried with hydrocolloids |
US3539365A (en) * | 1967-02-13 | 1970-11-10 | Fmc Corp | Dispersing and stabilizing agent comprising beta-1,4 glucan and cmc and method for its preparation |
US4156021A (en) * | 1976-03-03 | 1979-05-22 | Maxfibe, Inc. | Oleaginous fibrous simulated food product |
US4109018A (en) * | 1976-05-27 | 1978-08-22 | Thompson Jerome B | Low calorie diet bread |
US4143163A (en) * | 1976-06-30 | 1979-03-06 | Maxfibe, Inc. | Coated fibrous cellulose product and process |
AU508480B2 (en) * | 1977-04-13 | 1980-03-20 | Asahi Kasei Kogyo Kabushiki Kaisha | Microcrystalline cellulose excipient and pharmaceutical composition containing thesame |
US4219580A (en) * | 1978-06-29 | 1980-08-26 | Pfizer Inc. | Flour substitutes |
US4232052A (en) * | 1979-03-12 | 1980-11-04 | National Starch And Chemical Corporation | Process for powdering high fat foodstuffs |
US4664915A (en) * | 1981-07-01 | 1987-05-12 | Bristol-Myers Company | Compressed and formed alkaline component suitable for use in buffered aspirin product |
DK148784D0 (en) * | 1984-02-29 | 1984-02-29 | Nexus Aps | POWDER PRODUCTS |
CA1261261A (en) * | 1985-03-08 | 1989-09-26 | Dev K. Mehra | Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation |
US4814195A (en) * | 1987-03-20 | 1989-03-21 | Winters Canning Co. | Reduced calorie peanut butter product |
US5019397A (en) * | 1988-04-21 | 1991-05-28 | Alza Corporation | Aqueous emulsion for pharmaceutical dosage form |
US4980193A (en) * | 1988-06-17 | 1990-12-25 | Fmx Corporation | Microcrystalline cellulose-based stabilizer system for dry mix instant chocolate drink |
US4911946A (en) * | 1988-06-24 | 1990-03-27 | The Nutra Sweet Company | Carbohydrate cream substitute |
GB8829088D0 (en) * | 1988-12-13 | 1989-01-25 | Smith Kline French Lab | Compounds |
US5011701A (en) * | 1988-12-30 | 1991-04-30 | Kraft General Foods, Inc. | Low calorie food products having smooth, creamy, organoleptic characteristics |
US5026569A (en) * | 1989-01-18 | 1991-06-25 | The Procter & Gamble Company | Cotton fiber particles for use in baked goods |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
DK0475998T3 (en) * | 1989-05-26 | 1994-05-30 | Fmc Corp | Fat-like aqueous food filler comprising microcrystalline cellulose and a galactomannan gum |
EP0458484A3 (en) * | 1989-05-26 | 1992-12-09 | The Kendall Company | Rubber-based adhesive tapes |
DK161743C (en) * | 1989-07-03 | 1992-02-17 | Niro Atomizer As | PROCEDURE AND APPARATUS FOR AGGLOMERATION OF A POWDER-SHAPED MATERIAL |
US5132212A (en) * | 1989-11-17 | 1992-07-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Scl gene, and a hematopoietic growth and differentiation factor encoded thereby |
US5158798A (en) * | 1990-02-05 | 1992-10-27 | Pfizer Inc. | Low-calorie fat substitute |
US5075115A (en) * | 1990-04-02 | 1991-12-24 | Fmc Corporation | Process for polymerizing poly(lactic acid) |
USH1229H (en) * | 1990-07-18 | 1993-09-07 | Fmc Corporation | Stabilizing agent for dry mix food products |
HU206824B (en) * | 1990-08-24 | 1993-01-28 | Biogal Gyogyszergyar | Process for the production of a table crystallizing in the monoclinic system, which contains light-, heat-, and moisture- sensitive active agents |
ATE171838T1 (en) * | 1991-01-16 | 1998-10-15 | Fmc Corp | CARRIER FOR ACTIVE INGREDIENTS AND SOLID DOSAGE FORMS PRODUCED THEREFROM |
US5132128A (en) * | 1991-04-17 | 1992-07-21 | The J. M. Smucker Company | Reduced calorie dessert topping |
US5209942A (en) * | 1991-11-27 | 1993-05-11 | Thomas J. Lipton, Co., Division Of Conopco, Inc. | Low fat/no fat salad dressing having mimetic functional properties fat and a process therefor |
CA2126441C (en) * | 1991-12-30 | 1999-12-21 | David F. Erkoboni | Microcrystalline cellulose spheronization composition |
EP0661934A4 (en) * | 1992-09-22 | 1996-07-24 | Fmc Corp | Product and process of making microcrystalline cellulose. |
US5338562A (en) * | 1992-11-25 | 1994-08-16 | Fmc Corporation | Low fat spread and process for making same |
TW260612B (en) * | 1993-01-05 | 1995-10-21 | Asahi Chemical Ind | |
CA2150372C (en) * | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
US5366742A (en) * | 1993-05-03 | 1994-11-22 | Fmc Corporation | Colloidal microcrystalline cellulose and barrier dispersant composition and method for manufacture |
US5441753A (en) * | 1994-01-28 | 1995-08-15 | Fmc Corporation | Coprocessed particulate bulking and formulating AIDS: their composition, production, and use |
US5505982A (en) * | 1994-01-28 | 1996-04-09 | Fmc Corporation | Chocolate confection |
US5462761A (en) * | 1994-04-04 | 1995-10-31 | Fmc Corporation | Microcrystalline cellulose and glucomannan aggregates |
US5447729A (en) * | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
US5429830A (en) * | 1994-07-08 | 1995-07-04 | Fmc Corporation | Marshmallow-type confections |
-
1996
- 1996-01-04 IL IL11667496A patent/IL116674A/en not_active IP Right Cessation
- 1996-01-04 IL IL13972896A patent/IL139728A/en not_active IP Right Cessation
- 1996-01-05 EP EP96907007A patent/EP0749300B1/en not_active Expired - Lifetime
- 1996-01-05 HU HU9602361A patent/HUP9602361A3/en unknown
- 1996-01-05 WO PCT/US1996/000539 patent/WO1996022080A1/en active Application Filing
- 1996-01-05 CA CA002183882A patent/CA2183882C/en not_active Expired - Fee Related
- 1996-01-05 AU AU50199/96A patent/AU708346B2/en not_active Ceased
- 1996-01-05 JP JP52234796A patent/JP3728321B2/en not_active Expired - Lifetime
- 1996-01-05 BR BR9605245A patent/BR9605245A/en not_active Application Discontinuation
- 1996-01-06 TW TW085100140A patent/TW505529B/en not_active IP Right Cessation
- 1996-06-10 US US08/660,553 patent/US5866166A/en not_active Expired - Lifetime
- 1996-07-08 US US08/676,654 patent/US5741524A/en not_active Expired - Lifetime
- 1996-09-06 FI FI963496A patent/FI963496A/en unknown
- 1996-09-06 NO NO19963733A patent/NO321771B1/en not_active IP Right Cessation
-
1997
- 1997-12-17 US US08/982,224 patent/US5858412A/en not_active Expired - Lifetime
-
2000
- 2000-11-16 IL IL13972800A patent/IL139728A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4744987A (en) * | 1985-03-08 | 1988-05-17 | Fmc Corporation | Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation |
US4946685A (en) * | 1987-04-06 | 1990-08-07 | Alza Corporation | Cellulosic dosage form |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2761266A1 (en) * | 1997-03-28 | 1998-10-02 | Sanofi Sa | WET-GRANULATED PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF AN N-PIPERIDINO-3-PYRAZOLECARBOXAMIDE DERIVATIVE, ITS SALTS AND SOLVATES |
WO1998043636A1 (en) * | 1997-03-28 | 1998-10-08 | Sanofi-Synthelabo | Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates |
AU740486B2 (en) * | 1997-03-28 | 2001-11-08 | Sanofi-Aventis | Pharmaceutical composition for oral administration of a N-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates |
US6893659B2 (en) | 1997-03-28 | 2005-05-17 | Sanoti-Synthelabo | Pharmaceutical composition for oral administration of a N-piperidino-3- pyrazolecarboxamide derivative, its salts and their solvates |
WO1999061037A1 (en) * | 1998-05-22 | 1999-12-02 | Amway Corporation | Plant material composition |
US6232351B1 (en) | 1998-05-22 | 2001-05-15 | Amway Corporation | Co-processed botanical plant composition |
WO2000077088A1 (en) * | 1999-06-14 | 2000-12-21 | Centre National De La Recherche Scientifique | Microfibrillated and/or microcrystalline dispersion, in particular of cellulose, in an organic solvent |
US6967027B1 (en) | 1999-06-14 | 2005-11-22 | Centre National De La Recherche Scientifique | Microfibrillated and/or microcrystalline dispersion, in particular of cellulose, in an organic solvent |
US20050051922A1 (en) * | 2002-09-20 | 2005-03-10 | Avinash Nangia | Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same |
Also Published As
Publication number | Publication date |
---|---|
TW505529B (en) | 2002-10-11 |
HU9602361D0 (en) | 1996-11-28 |
NO963733L (en) | 1996-09-06 |
US5866166A (en) | 1999-02-02 |
IL139728A (en) | 2003-06-24 |
HUP9602361A2 (en) | 1997-08-28 |
AU5019996A (en) | 1996-08-07 |
IL116674A0 (en) | 1996-05-14 |
CA2183882C (en) | 2000-08-22 |
CA2183882A1 (en) | 1996-07-25 |
IL139728A0 (en) | 2002-02-10 |
NO963733D0 (en) | 1996-09-06 |
BR9605245A (en) | 1997-09-16 |
IL116674A (en) | 2003-05-29 |
JP3728321B2 (en) | 2005-12-21 |
EP0749300A1 (en) | 1996-12-27 |
EP0749300A4 (en) | 2001-09-05 |
EP0749300B1 (en) | 2009-10-14 |
FI963496A0 (en) | 1996-09-06 |
AU708346B2 (en) | 1999-08-05 |
US5741524A (en) | 1998-04-21 |
FI963496A (en) | 1996-11-06 |
JPH10512862A (en) | 1998-12-08 |
HUP9602361A3 (en) | 2001-12-28 |
US5858412A (en) | 1999-01-12 |
NO321771B1 (en) | 2006-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2183882C (en) | Pharmaceutical excipient having improved compressibility | |
US5725883A (en) | Pharmaceutical excipient having improved compressibility | |
US5948438A (en) | Pharmaceutical formulations having improved disintegration and/or absorptivity | |
US6866867B2 (en) | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | |
US6106865A (en) | Pharmaceutical excipient having improved compressibility | |
US6471994B1 (en) | Pharmaceutical excipient having improved compressibility | |
US6936277B2 (en) | Pharmaceutical excipient having improved compressibility | |
US5733578A (en) | Directly compressible high load acetaminophen formulations | |
US6852336B2 (en) | Directly compressible high load acetaminophen formulations | |
AU737464B2 (en) | Pharmaceutical excipient having improved compressibility | |
MXPA96003746A (en) | Pharmaceutical excipient that has compressibility best | |
MXPA96003745A (en) | Pharmaceutical excipient that has compressibility best |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AZ BY KZ RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2183882 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996907007 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 963496 Country of ref document: FI Ref document number: 1019960704934 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 1996 522347 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1996907007 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |